EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma

Bibliography

• Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med 2008;359(11):1143-54
   PubMed Web of Science ®Google Scholar
• Marur S, Forastiere AA. Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin Proc 2008;83(4):489-501
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55(2):74-108
   PubMed Web of Science ®Google Scholar
• Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000;103(2):211-25
   PubMed Web of Science ®Google Scholar
• Lin SY, Makino K, Xia W, Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 2001;3(9):802-8
   PubMed Web of Science ®Google Scholar
• Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5(5):341-54
   PubMed Web of Science ®Google Scholar
• Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 2006;6(9):714-27
   PubMed Web of Science ®Google Scholar
• Goldstein NI, Prewett M, Zuklys K, Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995;1(11):1311-8
   PubMed Web of Science ®Google Scholar
• Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6(4):443-6
   PubMed Web of Science ®Google Scholar
• Li J, Zhao M, He P, Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res 2007;13(12):3731-7
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354(6):567-78
   PubMed Web of Science ®Google Scholar
• Cohen EE, Lingen MW, Vokes EE. The expanding role of systemic therapy in head and neck cancer. J Clin Oncol 2004;22(9):1743-52
   PubMed Web of Science ®Google Scholar
• Leon X, Hitt R, Constenla M, A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Clin Oncol (R Coll Radiol) 2005;17(6):418-24
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Mesia R, Rivera F, Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359(11):1116-27
   PubMed Web of Science ®Google Scholar
• Boshoff C, Posner M. Targeting EGFR in head and neck cancer: a decade of progress. Nat Clin Pract Oncol 2009;6(3):123
   PubMedGoogle Scholar
• Harari PM, Wheeler DL, Grandis JR. Molecular target approaches in head and neck cancer: epidermal growth factor receptor and beyond. Semin Radiat Oncol 2009;19(1):63-8
   PubMed Web of Science ®Google Scholar
• Morgan S, Grandis JR. ErbB receptors in the biology and pathology of the aerodigestive tract. Exp Cell Res 2009;315(4):572-82
   PubMed Web of Science ®Google Scholar
• Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993;53(15):3579-84
   PubMed Web of Science ®Google Scholar
• Shin DM, Ro JY, Hong WK, Hittelman WN. Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 1994;54(12):3153-9
   PubMed Web of Science ®Google Scholar
• Albanell J, Codony-Servat J, Rojo F, Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res 2001;61(17):6500-10
   PubMed Web of Science ®Google Scholar
• Amador ML, Oppenheimer D, Perea S, An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res 2004;64(24):9139-43
   PubMed Web of Science ®Google Scholar
• Erjala K, Sundvall M, Junttila TT, Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res 2006;12(13):4103-11
   PubMed Web of Science ®Google Scholar
• Temam S, Kawaguchi H, El-Naggar AK, Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 2007;25(16):2164-70
   PubMed Web of Science ®Google Scholar
• Chung CH, Ely K, McGavran L, Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006;24(25):4170-6
   PubMed Web of Science ®Google Scholar
• Stewart JS, Cohen EE, Licitra L, Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol 2009;27(11):1864-71
   PubMed Web of Science ®Google Scholar
• Gschwind A, Hart S, Fischer OM, Ullrich A. TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells. Embo J 2003;22(10):2411-21
   PubMed Web of Science ®Google Scholar
• Ekstrand AJ, Sugawa N, James CD, Collins VP. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci USA 1992;89(10):4309-13
   PubMed Web of Science ®Google Scholar
• Huang HS, Nagane M, Klingbeil CK, The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 1997;272(5):2927-35
   PubMed Web of Science ®Google Scholar
• Sok JC, Coppelli FM, Thomas SM, Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006;12(17):5064-73
   PubMed Web of Science ®Google Scholar
• Rubin Grandis J, Melhem MF, Gooding WE, Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998;90(11):824-32
   PubMed Web of Science ®Google Scholar
• Ang KK, Berkey BA, Tu X, Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002;62(24):7350-6
   PubMed Web of Science ®Google Scholar
• Licitra L, Rolland F, Bokemeyer E, Biomarker potential of EGFR gene copy number by FISH in the phase III EXTREME study: platinum-based CT plus cetuximab in first-line R/M SCCHN. American Society of Clinical Oncology (ASCO); 2009. J Clin Oncol 2009;27: abstract 6005
   Google Scholar
• Xia W, Lau YK, Zhang HZ, Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res 1999;5(12):4164-74
   PubMed Web of Science ®Google Scholar
• Bei R, Budillon A, Masuelli L, Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients. J Pathol 2004;204(3):317-25
   PubMed Web of Science ®Google Scholar
• Van Schaeybroeck S, Karaiskou-McCaul A, Kelly D, Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. Clin Cancer Res 2005;11(20):7480-9
   PubMed Web of Science ®Google Scholar
• Benhar M, Engelberg D, Levitzki A. Cisplatin-induced activation of the EGF receptor. Oncogene 2002;21(57):8723-31
   PubMed Web of Science ®Google Scholar
• Bandyopadhyay D, Mandal M, Adam L, Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J Biol Chem 1998;273(3):1568-73
   PubMed Web of Science ®Google Scholar
• Chen DJ, Nirodi CS. The epidermal growth factor receptor: a role in repair of radiation-induced DNA damage. Clin Cancer Res 2007;13(22 Pt 1):6555-60
   PubMed Web of Science ®Google Scholar
• Fan Z, Baselga J, Masui H, Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993;53(19):4637-42
   PubMed Web of Science ®Google Scholar
• Nyati MK, Morgan MA, Feng FY, Lawrence TS. Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer 2006;6(11):876-85
   PubMed Web of Science ®Google Scholar
• Erjala K, Zhang N, Sundvall M, Concomitant chemoirradiation with vinorelbine and gefitinib induces additive effect in head and neck squamous cell carcinoma cell lines in vitro. Radiother Oncol 2007;85(1):138-45
   PubMed Web of Science ®Google Scholar
• Mendelsohn J, Fan Z. Epidermal growth factor receptor family and chemosensitization. J Natl Cancer Inst 1997;89(5):341-3
   PubMed Web of Science ®Google Scholar
• Zhang N, Erjala K, Kulmala J, Concurrent cetuximab, cisplatin, and radiation for squamous cell carcinoma of the head and neck in vitro. Radiother Oncol 2009;92(3):388-92
   PubMed Web of Science ®Google Scholar
• Schmidt-Ullrich RK, Mikkelsen RB, Dent P, Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 1997;15(10):1191-7
   PubMed Web of Science ®Google Scholar
• Dittmann K, Mayer C, Fehrenbacher B, Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem 2005;280(35):31182-9
   PubMed Web of Science ®Google Scholar
• Contessa JN, Hampton J, Lammering G, Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells. Oncogene 2002;21(25):4032-41
   PubMed Web of Science ®Google Scholar
• Peltola K, Hollmen M, Maula SM, Pim-1 kinase expression predicts radiation response in squamocellular carcinoma of head and neck and is under the control of epidermal growth factor receptor. Neoplasia 2009;11(7):629-36
   PubMed Web of Science ®Google Scholar
• Akimoto T, Hunter NR, Buchmiller L, Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 1999;5(10):2884-90
   PubMed Web of Science ®Google Scholar
• Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999;59(8):1935-40
   PubMed Web of Science ®Google Scholar
• Available from: www.clinicaltrials.gov
   Google Scholar
• Available from: www.fda.gov
   Google Scholar
• Available from: www.emea.europa.eu
   Google Scholar
• Curran D, Giralt J, Harari PM, Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol 2007;25(16):2191-7
   PubMed Web of Science ®Google Scholar
• Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet 2008;371(9625):1695-709
   PubMed Web of Science ®Google Scholar
• Pfister DG, Su YB, Kraus DH, Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 2006;24(7):1072-8
   PubMed Web of Science ®Google Scholar
• Langer CJ, Lee JW, Patel UA, Preliminary analysis of ECOG 3303: concurrent radiation (RT), cisplatin (DDP) and cetuximab (C) in unresectable, locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN). American Society of Clinical Oncology (ASCO); 2008. J Clin Oncol 2008;26: abstract 6006
   Google Scholar
• Argiris AE, Gibson MK, Heron DE, Phase II trial on neoadjuvant docetaxel (T), cisplatin (P), and cetuximab (E) followed by concurrent radiation (X), P, and E in locally advanced head and neck cancer (HNC). American Society of Clinical Oncology (ASCO); 2008. J Clin Oncol 2008;26: abstract 6002
   Google Scholar
• Mesia R, Vazquez S, Grau JJ, A single-arm phase II trial to evaluate the combination of cetuximab plus docetaxel, cisplatin, and 5-fluorouracil (TPF) as induction chemotherapy (IC) in patients (pts) with unresectable SCCHN. American Society of Clinical Oncology (ASCO) 2009. J Clin Oncol 2009;27: abstract 6015
   Google Scholar
• Merke C, Wickart-Johansson G, Sjödin H, Upfront chemotherapy and accelerated radiotherapy with EGFR inhibition for locally advanced inoperable head and neck cancer. American Society of Clinical Oncology (ASCO); 2009. J Clin Oncol 2009;27: abstract 6040
   Google Scholar
• Vermorken JB, Trigo J, Hitt R, Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007;25(16):2171-7
   PubMed Web of Science ®Google Scholar
• Burtness B, Goldwasser MA, Flood W, Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005;23(34):8646-54
   PubMed Web of Science ®Google Scholar
• Crombet T, Osorio M, Cruz T, Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004;22(9):1646-54
   PubMed Web of Science ®Google Scholar
• Wirth LJ, Posner MR, Tishler RB, Phase I study of panitumumab + chemoradiotherapy (CRT) for head and neck cancer (HNC). American Society of Clinical Oncology (ASCO); 2008. J Clin Oncol 2008;26: abstract 6007
   Google Scholar
• Bastholt L, Specht L, Jensen K, Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck. Radiother Oncol 2007;85(1):24-8
   PubMed Web of Science ®Google Scholar
• Krishnamurthyreddy B, Vidyasagar MS, Koteshwar R, A phase IIb 4-arm open-label randomized study to assess the safety and efficacy of h-R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (stage III or IVA) inoperable head and neck cancer. American Society of Clinical Oncology (ASCO); 2009. J Clin Oncol 2009;27: abstract 6041
   Google Scholar
• Soulieres D, Senzer NN, Vokes EE, Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004;22(1):77-85
   PubMed Web of Science ®Google Scholar
• Cohen EE, Rosen F, Stadler WM, Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003;21(10):1980-7
   PubMed Web of Science ®Google Scholar
• Abidoye OO, Cohen EE, Wong SJ, A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). American Society of Clinical Oncology (ASCO); 2006. J Clin Oncol 2006;24(18S):5568
   Google Scholar
• Argiris A, Ghebremichael M, Gilbert B, A phase III randomized, placebo-controlled trial of docetaxel (D) with or without gefitinib (G) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): a trial of the Eastern Cooperative Oncology Group (ECOG). American Society of Clinical Oncology (ASCO); 2009. J Clin Oncol 2009;27: abstract 6011
   Google Scholar
• Siu LL, Soulieres D, Chen EX, Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol 2007;25(16):2178-83
   PubMed Web of Science ®Google Scholar
• Kim ES, Kies MS, Glisson BS, Final results of a phase II study of erlotinib, docetaxel and cisplatin in patients with metastatic/recurrent head and neck cancer. American Society of Clinical Oncology (ASCO); 2007. J Clin Oncol 2007;25(18S):6013
   Google Scholar
• Hainsworth JD, Spigel DR, Burris HA III, Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck. Cancer 2009;115(10):2138-46
   PubMed Web of Science ®Google Scholar
• Caponigro F, Romano C, Milano A, A phase I/II trial of gefitinib and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck. Anticancer Drugs 2008;19(7):739-44
   PubMed Web of Science ®Google Scholar
• Chen C, Kane M, Song J, Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer. J Clin Oncol 2007;25(31):4880-6
   PubMed Web of Science ®Google Scholar
• Herchenhorn D, Dias FL, Pineda RM, Phase II study of erlotinib combined with cisplatin and radiotherapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN). American Society of Clinical Oncology (ASCO); 2007. J Clin Oncol 2007;25(18S): abstract 6033
   Google Scholar
• Chung CH, Mirakhur B, Chan E, Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 2008;358(11):1109-17
   PubMed Web of Science ®Google Scholar
• O'Neil BH, Allen R, Spigel DR, High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol 2007;25(24):3644-8
   PubMed Web of Science ®Google Scholar
• Saif MW, Peccerillo J, Potter V. Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature. Cancer Chemother Pharmacol 2009;63(6):1017-22
   PubMed Web of Science ®Google Scholar
• Baselga J, Pfister D, Cooper MR, Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000;18(4):904-14
   PubMed Web of Science ®Google Scholar
• Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006;6(10):803-12
   PubMed Web of Science ®Google Scholar
• Giro C, Berger B, Bolke E, High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes. Radiother Oncol 2009;90(2):166-71
   PubMed Web of Science ®Google Scholar
• Berger B, Belka C. Severe skin reaction secondary to concomitant radiotherapy plus cetuximab. Radiat Oncol 2008;3:5
   PubMed Web of Science ®Google Scholar
• Cersosimo RJ. Gefitinib: an adverse effects profile. Expert Opin Drug Saf 2006;5(3):469-79
   PubMed Web of Science ®Google Scholar
• Grandis JR, Lai SY, Esteve FR, Erlotinib (E) as adjuvant treatment for patients (pts) with resected head and neck squamous cell carcinoma (HNSCC) with evaluation of neoadjuvant biomarker modulation with E with or without sulindac S: a feasibility report. American Society of Clinical Oncology (ASCO); 2008. J Clin Oncol 2008;26: abstract 6037
   Google Scholar
• Gibson MK, Kies M, Kim S, Cetuximab (C) and bevacizumab (B) in patients with recurrent or metastatic head and neck squamous cell carcinoma: an updated report. American Society of Clinical Oncology (ASCO); 2009. J Clin Oncol 2009;27: abstract 6049
   Google Scholar
• Cohen EE, Davis DW, Karrison TG, Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol 2009;10(3):247-57
   PubMed Web of Science ®Google Scholar
• Janne PA, Gray N, Settleman J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov 2009;8(9):709-23
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350(21):2129-39
   PubMed Web of Science ®Google Scholar
• Paez JG, Janne PA, Lee JC, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304(5676):1497-500
   PubMed Web of Science ®Google Scholar
• Vogel CL, Cobleigh MA, Tripathy D, Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20(3):719-26
   PubMed Web of Science ®Google Scholar
• Lee JW, Soung YH, Kim SY, Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res 2005;11(8):2879-82
   PubMed Web of Science ®Google Scholar
• Cohen EE, Lingen MW, Martin LE, Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res 2005;11(22):8105-8
   PubMed Web of Science ®Google Scholar
• Loeffler-Ragg J, Witsch-Baumgartner M, Tzankov A, Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. Eur J Cancer 2006;42(1):109-11
   PubMed Web of Science ®Google Scholar
• Agulnik M, da Cunha Santos G, Hedley D, Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. J Clin Oncol 2007;25(16):2184-90
   PubMed Web of Science ®Google Scholar
• Thomas F, Rochaix P, Benlyazid A, Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma. Clin Cancer Res 2007;13(23):7086-92
   PubMed Web of Science ®Google Scholar
• Herbst RS, Arquette M, Shin DM, Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23(24):5578-87
   PubMed Web of Science ®Google Scholar
• Hamilton M, Wolf JL, Rusk J, Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 2006;12(7 Pt 1):2166-71
   PubMed Web of Science ®Google Scholar
• Li J, Cusatis G, Brahmer J, Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther 2007;6(3):432-8
   PubMed Web of Science ®Google Scholar
• Lopez-Albaitero A, Lee SC, Morgan S, Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother 2009;58(11):1853-64
   PubMed Web of Science ®Google Scholar
• Karapetis CS, Khambata-Ford S, Jonker DJ, K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359(17):1757-65
   PubMed Web of Science ®Google Scholar
• Di Nicolantonio F, Martini M, Molinari F, Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26(35):5705-12
   PubMed Web of Science ®Google Scholar
• Nagata Y, Lan KH, Zhou X, PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6(2):117-27
   PubMed Web of Science ®Google Scholar
• Berns K, Horlings HM, Hennessy BT, A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007;12(4):395-402
   PubMed Web of Science ®Google Scholar
• Sergina NV, Rausch M, Wang D, Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007;445(7126):437-41
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316(5827):1039-43
   PubMed Web of Science ®Google Scholar
• Wheeler DL, Huang S, Kruser TJ, Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 2008;27(28):3944-56
   PubMed Web of Science ®Google Scholar
• Ruiz-Godoy RL, Garcia-Cuellar CM, Herrera Gonzalez NE, Mutational analysis of K-ras and Ras protein expression in larynx squamous cell carcinoma. J Exp Clin Cancer Res 2006;25(1):73-8
   PubMed Web of Science ®Google Scholar
• Al Sheikh Ali M, Gunduz M, Gunduz E, Lack of B-RAF mutations in head and neck squamous cell carcinoma. Folia Biol (Praha) 2008;54(5):157-61
   PubMed Web of Science ®Google Scholar
• Woenckhaus J, Steger K, Werner E, Genomic gain of PIK3CA and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinoma. J Pathol 2002;198(3):335-42
   PubMed Web of Science ®Google Scholar
• Poetsch M, Lorenz G, Kleist B. Detection of new PTEN/MMAC1 mutations in head and neck squamous cell carcinomas with loss of chromosome 10. Cancer Genet Cytogenet 2002;132(1):20-4
   PubMed Web of Science ®Google Scholar
• Kalish LH, Kwong RA, Cole IE, Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines. Clin Cancer Res 2004;10(22):7764-74
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-92
   PubMed Web of Science ®Google Scholar
• Zhang X, Gureasko J, Shen K, An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 2006;125(6):1137-49
   PubMed Web of Science ®Google Scholar
• Burgess AW, Cho HS, Eigenbrot C, An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 2003;12(3):541-52
   PubMed Web of Science ®Google Scholar
• Li S, Schmitz KR, Jeffrey PD, Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005;7(4):301-11
   PubMed Web of Science ®Google Scholar
• Sunada H, Magun BE, Mendelsohn J, MacLeod CL. Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc Natl Acad Sci USA 1986;83(11):3825-9
   PubMed Web of Science ®Google Scholar
• Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 2002;277(48):46265-72
   PubMed Web of Science ®Google Scholar
• Wood ER, Truesdale AT, McDonald OB, A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004;64(18):6652-9
   PubMed Web of Science ®Google Scholar
• Shin DM, Donato NJ, Perez-Soler R, Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 2001;7(5):1204-13
   PubMed Web of Science ®Google Scholar
• Chan ATC, Hsu MM, Goh BC, A phase II study of cetuximab (C225) in combination with carboplatin in patients (pts) with recurrent or metastatic nasopharyngeal carcinoma (NPC) who failed to a platinum-based chemotherapy [abstract 2000]. American Society of Clinical Oncology (ASCO); 2003
   Google Scholar
• Baselga J, Trigo JM, Bourhis J, Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23(24):5568-77
   PubMed Web of Science ®Google Scholar
• Bourhis J, Rivera F, Mesia R, Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2006;24(18):2866-72
   PubMed Web of Science ®Google Scholar
• Hitt R, Irigoyen A, Nunez J, Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck (SCCHN): Spanish Head and Neck Cancer Group (TTCC). American Society of Clinical Oncology (ASCO); 2007. J Clin Oncol 2007;25(18S): abstract 6012
   PubMed Web of Science ®Google Scholar
• Knoedler M, Gauler TC, Matzdorff A, Phase II trial to evaluate efficacy and toxicity of cetuximab plus docetaxel in platinum pretreated patients with recurrent and/or metastatic head and neck cancer. American Society of Clinical Oncology (ASCO); 2008. J Clin Oncol 2008;26: abstract 6066
   Google Scholar
• Cohen EE, Kane MA, List MA, Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 2005;11(23):8418-24
   PubMed Web of Science ®Google Scholar
• Wheeler RH, Jones D, Sharma P, Clinical and molecular phase II study of gefitinib in patients (pts) with recurrent squamous cell cancer of the head and neck (H&N Ca) [abstract 5531]. American Society of Clinical Oncology (ASCO); 2005
   Google Scholar
• Kirby AM, A'Hern RP, D'Ambrosio C, Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer. Br J Cancer 2006;94(5):631-6
   PubMed Web of Science ®Google Scholar
• Chua DT, Sham J, Au G. A phase II trial of gefitinib in recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy. American Society of Clinical Oncology (ASCO); 2007. J Clin Oncol 2007;25(18S): abstract 6042
   Google Scholar
• Robert F, Ezekiel MP, Spencer SA, Phase I study of anti–epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001;19(13):3234-43
   PubMed Web of Science ®Google Scholar
• Kies MS, Garden AS, Holsinger C, Induction chemotherapy (CT) with weekly paclitaxel, carboplatin, and cetuximab for squamous cell carcinoma of the head and neck (HN). American Society of Clinical Oncology (ASCO); 2006. J Clin Oncol 2006;24(18S): abstract 5520
   Google Scholar
• Colantonio I, Numico G, Crosetto N, Treatment of locally advanced head-and-neck squamous carcinomas with chemotherapy alternated to radiation and Cetuximab (ALTERCC Phase II study) [abstract 42]. European Society for Medical Oncology (ESMO); 2007
   Google Scholar
• Merlano MC, Numico G, Russi EG, Cetuximab (c-mab) and chemo-radiation (CT-RT) for loco-regional advanced squamous cell carcinoma of the head and neck (HNC): a phase II study [abstract 6043]. American Society of Clinical Oncology (ASCO); 2007
   Google Scholar
• Kuhnt T, Sandner A, Wendt TG, Concomitant hyperfractionated accelerated radiotherapy (HART) with cisplatin and concurrent cetuximab for locoregionally advanced squamous cell head and neck cancer: a phase I dose escalation trial [abstract 6029]. American Society of Clinical Oncology (ASCO); 2008
   Google Scholar
• Tabernero J, Hitt R, Cervantes A, Panitumumab (PMAB) administeed with chemoradiotherapy (CRT) following induction chemotherapy (IC) in the treatment of patients (PTS) with loco-regionally advanced squamous cell carcinoma of the head and neck [abstract 690]. European Society for Medical Oncology (ESMO); 2008
   Google Scholar
• Meluch AA, Spigel D, Burris HA, Combined modality therapy with radiation therapy (RT), chemotherapy, bevacizumab, and erlotinib in the treatment of patients (pts) with locally advanced squamous carcinoma of the head and neck. American Society of Clinical Oncology (ASCO); 2009. J Clin Oncol 2009;27: abstract 6012
   Google Scholar
• Kane MA, Cohen E, List M, Phase II study of 250 mg gefitinib in advanced squamous cell carcinoma of the head and neck (SCCHN) [abstract 5586]. American Society of Clinical Oncology (ASCO); 2004
   Google Scholar
• Ahmed SM, Cohen EE, Haraf DJ, Updated results of a phase II trial integrating gefitinib (G) into concurrent chemoradiation (CRT) followed by G adjuvant therapy for locally advanced head and neck cancer (HNC) [abstract 6028]. American Society of Clinical Oncology (ASCO); 2007
   Google Scholar
• Rueda A, Medina JA, Mesia R, Gefitinib plus concomitant boost accelerated radiation (AFX-CB) and concurrent weekly cisplatin for locally advanced unresectable squamous cell head and neck carcinomas (SCCHN): a phase II study [abstract 6031]. American Society of Clinical Oncology (ASCO); 2007
   Google Scholar
• Tan EH, Goh C, Loy A, Phase II study of gefitinib in combination with cisplatin and concurrent radiotherapy in patients with stage III/IV squamous cell head and neck cancer and to analyze the effect of gefitinib on tumour gene expression [abstract 207]. European Society for Medical Oncology (ESMO); 2008
   Google Scholar
• Rodrigues CP, Adelstein DJ, Saxton JP, Multiagent concurrent chemoradiotherapy (MACCRT) and gefitinib in locoregionally advanced head and neck squamous cell cancer (HNSCC) [abstract 6037]. American Society of Clinical Oncology (ASCO); 2009
   Google Scholar
• Bourhis J, Harrington K, Rosine D, A phase I, open-label study (EGF100262) of lapatinib plus chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Ann Oncol 2006;17(Suppl 9):180
   Google Scholar
• del Campo JM, Sebastian P, Hitt R, Effect of lapatinib monotherapy of apoptosis and proliferation: results of a phase II randomised study in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) [abstract 6880]. European Society for Medical Oncology (ESMO); 2008
   Google Scholar
• Harrington KJ, El-Hariry IA, Holford CS, Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 2009;27(7):1100-7
   PubMed Web of Science ®Google Scholar
• Lai SY, Koppikar P, Thomas SM, Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms. J Clin Oncol 2009;27(8):1235-42
   PubMed Web of Science ®Google Scholar